{"id":1346,"date":"2026-02-09T10:48:00","date_gmt":"2026-02-09T10:48:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/02\/09\/antibodies-in-the-brain\/"},"modified":"2026-02-09T10:48:00","modified_gmt":"2026-02-09T10:48:00","slug":"antibodies-in-the-brain","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/02\/09\/antibodies-in-the-brain\/","title":{"rendered":"Antibodies in the brain"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2026%2F02%2Fantibodies-in-the-brain%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>This week I was arguing that PIRA is a terrible concept because a significant element is due to actions outside the CNS&#8230;I suggested that most antibody delivered never reach the CNS.<\/p>\n<p>To the average of 80Kg volunteers they give 6mg\/kg = 480mg (more than any MS antibody except ocrelizumab and 24 times the ofatumumab dose), 18mg\/kg = 1040mg (more than rituximab and any approved MS antibody) and 36mg\/kg = 2880mg. Even at the low dose there was over 100 times more antibody circulating than reported with ofatumumab. at about a maximum of about 1microgramme\/microlitre so at 99.9% exclusion that is 1ng\/mL which is not a lot<\/p>\n<p>Curtin F, Vidal V, Bernard C, Kromminga A, Lang AB, Porchet H. Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study. MAbs. 2016;8:854-60. doi: 10.1080\/19420862.2016.1168956. Epub 2016 Mar 30. PMID: 27030142; PMCID: PMC4968100.<\/p>\n<p>GNbAC1 is a humanized IgG4 monoclonal antibody antagonist of Mulitple Sclerosis Retrovirus Envelope (MSRV-Env), a protein that could play a critical role in multiple sclerosis. This randomized placebo-controlled dose-escalation study evaluated the safety and pharmacokinetics of GNbAC1 in 21 healthy volunteers after single intravenous infusion at doses of 6, 18 and 36 mg\/kg. Lumbar punctures were performed at days 2, 15 or 29 to measure GNbAC1 concentrations in cerebrospinal fluid (CSF). GNbAC1 was well tolerated. Serum data show a dose-linear pharmacokinetics. A mean CSF\/serum ratio of <strong>0.12%<\/strong>  (~99.9% excluded) was observed at Day 2, increasing to 0.39% (99.6% excluded&#8230;.but if the half-life is different between the blood and the brain this may not be the case&#8230;) at Day 15 and 0.42% at Day 29 (Still more than 99% excluded, when there is 75% less antibody circulating). A relationship between GNbAC1 CSF\/serum ratio and albumin CSF\/serum ratio and a relationship at the limit of statistical significance with the timing of CSF sampling was shown<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2026\/02\/antibodies-in-the-brain\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=antibodies-in-the-brain\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet This week I was arguing that PIRA is a terrible concept because a significant element is due to actions outside the CNS&#8230;I suggested that most antibody delivered never reach the CNS. To the average of 80Kg volunteers they give 6mg\/kg = 480mg (more than any MS antibody except ocrelizumab and 24 times the ofatumumab&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1346","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1346"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1346\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}